IP Library Patent Application 11219322
Patent Application
App. No. 11/219,322

Method of delaying ejaculation

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/219,322
Abstract

The invention provides a method of delaying ejaculation. The method comprises administering an effective amount of a tramadol material to a human male prior to sexual intercourse. The method is particularly useful for treating premature ejaculation.

Claims (19)

1 . A method of delaying ejaculation comprising administering an effective amount of a tramadol material to a human male prior to sexual intercourse.

2 . The method of claim 1 wherein the tramadol material is tramadol or a pharmaceutically-acceptable salt thereof.

3 . The method of claim 2 wherein the tramadol material is (±) cis-tramadol or a pharmaceutically-acceptable salt thereof.

4 . The method of claim 3 wherein a dose of from about 10 to about 50 milligrams of the tramadol or the pharmaceutically-acceptable salt thereof is administered to the male.

5 . The method of claim 4 wherein a dose of from about 15 to about 35 milligrams of the tramadol or the pharmaceutically-acceptable salt thereof is administered to the male.

6 . The method of claim 5 wherein a dose of about 25 milligrams of the tramadol or the pharmaceutically-acceptable salt thereof is administered to the male.

7 . The method of claim 3 wherein a (+)-enantiomer of the cis-tramadol or the pharmaceutically-acceptable salt thereof is administered to the male.

8 . The method of claim 3 wherein a (−)-enantiomer of the cis-tramadol or the pharmaceutically-acceptable salt thereof is administered to the male.

9 . The method of claim 3 wherein the tramadol material is (±) cis-tramadol hydrochloride.

10 . The method of claim 9 wherein a dose of from about 10 to about 50 milligrams of the tramadol hydrochloride is administered to the male.

11 . The method of claim 10 wherein a dose of from about 15 to about 35 milligrams of the tramadol hydrochloride is administered to the male.

12 . The method of claim 11 wherein a dose of about 25 milligrams of the tramadol hydrochloride is administered to the male.

13 . The method of any one of claims 1 - 12 wherein the tramadol material is administered from about 30 minutes to about 60 minutes prior to sexual intercourse.

14 . The method of any one of claims 1 - 12 wherein the tramadol material is administered orally.

15 . The method of claim 13 wherein the tramadol material is administered orally.

16 . The method of any one of claims 1 - 12 wherein the male suffers from premature ejaculation.

17 . The method of claim 13 wherein the male suffers from premature ejaculation.

18 . The method of claim 14 wherein the male suffers from premature ejaculation.

19 . The method of claim 15 wherein the male suffers from premature ejaculation.

Assignments (4)
MERGER Recorded Aug 20, 2015
From: VYRIX PHARMACEUTICALS, INC.
To: ROSEWIND CORPORATION
Reel/Frame 036379/0212 →
CERTIFICATES OF CONVERSION AND INCORPORATION Recorded Aug 20, 2015
From: ROSEWIND CORPORATION
To: AYTU BIOSCIENCE, INC.
Reel/Frame 036399/0178 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 2, 2014
From: AMPIO PHARMACEUTICALS, INC.
To: VYRIX PHARMACEUTICALS, INC.
Reel/Frame 031873/0253 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 5, 2013
From: DMI BIOSCIENCES, INC.
To: AMPIO PHARMACEUTICALS, INC.
Reel/Frame 031141/0581 →